News
The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...
Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn't require an ...
The recent move to introduce an “Amazon-style” prescription tracking in the NHS App is a crucial first step. People want ...
From trade associations to medtech innovators and biotech start-ups, here’s a comprehensive look at the latest boardroom ...
AI, integrated customer journeys, and breaking down internal silos aren’t just trends – they’re business imperatives. In this ...
When Tidmarsh was appointed to CDER, the FDA emphasised his academic and clinical credentials – including his role as ...
"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their ...
President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) ...
The problem of medical misinformation on the Internet was brewing before the COVID-19 pandemic, but the combustible discourse ...
The foundational model could also assist Google and partner Samsung in an ongoing rivalry with Apple, currently the leader in ...
At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its ...
The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results